News
GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...
3d
ADWEEK on MSNSerena Williams Goes Public With GLP-1 Use in Ro's Push to Normalize Weight Loss Drugs
Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...
2don MSN
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
However, the drugmaker has excellent long-term prospects.
Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
4d
24/7 Wall St. on MSNEli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.
When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...
In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...
After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...
Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how ...
Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results